Article
An investigative combination therapy combining chemotherapy and immunotherapy of adoptive cell transfer with tumor infiltrating lymphocytes, followed by interleukin-2, is labor-intensive but a feasible therapy with a high response rate in treated patients, according to researchers.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.